sinc
discoveri
ebola
viru
pathogen
respons
increas
number
widespread
epidem
took
place
western
africa
decemb
june
result
total
report
case
report
death
april
world
health
organ
declar
recent
epidem
public
health
emerg
intern
concern
call
intensifi
effort
develop
therapeut
agent
target
ebola
although
largescal
epidem
may
end
emerg
sporad
new
case
continu
pose
risk
futur
ebola
viru
diseas
evd
often
consid
diseas
poverti
take
place
form
sudden
outbreak
amongst
poor
popul
limit
mani
diseas
poverti
research
drug
develop
evd
neglect
mani
year
commerci
unattract
drug
develop
invest
signific
resourc
exampl
studi
reveal
period
new
approv
drug
specif
indic
tropic
diseas
account
new
approv
nonetheless
recent
evd
outbreak
led
acceler
de
novo
drug
develop
effort
effort
promot
expedit
approv
process
regul
us
food
drug
administr
fda
european
medicin
yet
year
sinc
start
epidem
result
mani
experiment
drug
consid
either
question
neg
potenti
vaccin
consid
true
date
none
experiment
drug
fulli
approv
treatment
prevent
evd
due
urgent
need
effect
access
evd
treatment
addit
effort
studi
approv
establish
drug
potenti
antievd
therapeut
agent
concept
known
drug
repurpos
drug
concept
may
signific
advantag
case
evd
overcom
limit
experiment
drug
develop
first
repurpos
drug
usual
wellknown
safeti
pharmacokinet
profil
lead
shorter
develop
cycl
lower
addit
drug
may
often
tap
alreadi
establish
manufactur
distribut
network
shorten
product
deliveri
time
case
rapidli
spread
epidem
final
depend
repurpos
drug
identifi
may
alreadi
market
gener
clear
advantag
countri
resourcepoor
health
care
system
varieti
literatur
review
publish
potenti
therapeut
target
evd
also
includ
overview
possibl
candid
drug
howev
systemat
review
dedic
repurpos
therapeut
agent
target
evd
exist
date
herein
present
systemat
review
aim
identifi
potenti
drug
repurpos
candid
assess
scientif
evid
avail
efficaci
undertook
systemat
review
base
priori
protocol
regist
prospero
publish
peerreview
systemat
review
report
accord
prefer
report
item
systemat
review
metaanalys
prisma
studi
design
includ
drug
librari
screen
studi
yield
least
approv
therapeut
agent
includ
high
throughput
screen
studi
virtual
silico
drug
screen
preclin
trial
includ
vitro
trial
studi
anim
model
clinic
trial
includ
random
control
trial
control
clinic
trial
prospect
retrospect
compar
cohort
studi
studi
crosssect
studi
case
seri
case
report
potenti
repurpos
drug
select
assess
must
fulfil
follow
criteria
drug
alreadi
approv
least
regulatori
author
us
food
drug
administr
fda
european
medicin
agenc
ema
japan
pharmaceut
medic
devic
agenc
pmda
drug
posit
vitro
studi
outcom
least
addit
anim
clinic
trial
restrict
type
particip
preclin
clinic
trial
addit
restrict
type
set
includ
studi
publish
year
discoveri
evd
restrict
type
compar
primari
outcom
includ
mortal
sequela
infect
seriou
advers
event
secondari
outcom
includ
advers
event
outcom
collect
report
extract
outcom
data
form
eg
dichotom
continu
report
includ
studi
includ
articl
report
english
german
french
spanish
languag
includ
articl
publish
scientif
journal
well
unpublish
one
literatur
search
strategi
develop
use
medic
subject
head
text
word
relat
evd
perform
systemat
literatur
search
medlin
embas
cochran
central
regist
control
trial
search
carri
januari
studi
publish
januari
date
search
run
identifi
ongo
unpublish
studi
search
world
health
organ
intern
clinic
trial
registri
platform
clinicaltrialsgov
european
union
clinic
trial
regist
addit
search
refer
list
select
studi
well
websit
regulatori
author
fda
european
medicin
agenc
develop
search
strategi
help
inform
specialist
supplementari
file
databas
record
yield
search
strategi
export
endnot
version
clariv
analyt
usa
duplic
manual
remov
result
databas
search
record
identifi
sourc
document
depict
prisma
flow
diagram
formal
screen
preliminari
studi
screen
use
author
hs
oe
carri
pilot
screen
randomli
chosen
studi
search
result
spreadsheet
follow
pilot
screen
author
independ
screen
titl
abstract
yield
search
inclus
criteria
addit
screen
refer
list
select
articl
studi
select
titl
abstract
level
screen
elig
assess
full
text
articl
retriev
addit
inform
studi
author
necessari
resolv
question
elig
opinion
third
review
skl
sought
arriv
consensu
case
disagr
studi
inclus
document
reason
exclud
trial
fulltext
screen
level
neither
review
author
blind
journal
titl
studi
author
institut
report
result
studi
select
process
reason
exclus
fulltext
screen
level
use
prisma
flow
diagram
preliminari
data
extract
spreadsheet
use
conduct
pilot
test
carri
author
use
randomli
select
articl
data
extract
sheet
refin
accordingli
pilot
studi
refin
spread
sheet
use
author
independ
extract
data
item
includ
screen
preclin
clinic
studi
opinion
third
review
skl
sought
arriv
consensu
case
disagr
studi
author
contact
clarif
necessari
select
studi
includ
item
studi
type
extract
elig
item
avail
qualit
data
report
studi
exclud
review
thu
extract
howev
includ
studi
drew
conclus
base
qualit
data
report
conclus
separ
characterist
studi
tabl
follow
studi
select
data
extract
author
hs
oe
independ
select
drug
potenti
promis
result
base
aforement
drug
select
criteria
opinion
third
review
skl
sought
arriv
consensu
case
disagr
drug
inclus
two
author
oe
hs
independ
assess
risk
bia
includ
studi
risk
bia
vitro
studi
screen
studi
assess
due
nonexist
appropri
risk
bia
tool
studi
intern
valid
preclin
studi
anim
studi
assess
use
systemat
review
centr
laboratori
anim
experiment
risk
bia
per
instruct
outlin
cochran
handbook
systemat
review
intervent
newcastl
ottawa
scale
use
assess
risk
bia
nonrandom
studi
nation
heart
lung
blood
qualiti
assess
tool
case
seri
use
assess
qualiti
report
case
report
case
seri
due
lack
suitabl
risk
bia
tool
overal
risk
bia
judg
low
risk
unclear
risk
high
risk
wherea
overal
qualiti
report
judg
good
fair
poor
compar
individu
assess
oe
hs
initi
intend
conduct
quantit
analysi
primari
secondari
outcom
accord
protocol
systemat
howev
due
lack
adequ
number
suffici
homogen
studi
synthes
studi
result
narr
search
result
present
prisma
flow
diagram
figur
search
yield
record
remain
remov
duplic
follow
screen
titl
abstract
level
studi
still
includ
review
full
text
studi
inclus
criteria
studi
select
addit
studi
identifi
follow
refer
search
addit
ongo
studi
select
intern
clinic
trial
registri
platform
clinicaltrialsgov
european
union
clinic
trial
regist
websit
regulatori
author
summar
main
characterist
select
drug
screen
studi
list
posit
test
drug
confirm
regulatori
approv
supplementari
file
studi
heterogen
group
includ
highthroughput
screen
virtual
drug
screen
six
studi
introduc
new
drug
screen
methodolog
carri
pilot
screen
addit
differ
studi
use
vari
method
detect
posit
test
drug
commonli
appli
techniqu
measur
luciferas
activ
infect
cell
techniqu
use
appli
techniqu
includ
measur
inhibit
enhanc
green
fluoresc
protein
express
inhibit
betalactamas
activ
addit
conduct
drug
librari
screen
studi
includ
addit
preclin
trial
vitro
vivo
select
drug
relev
item
trial
extract
analyz
togeth
result
preclin
studi
summar
main
characterist
preclin
studi
examin
effect
potenti
drug
candid
evd
tabl
addit
data
preclin
studi
select
also
includ
relev
data
drug
screen
includ
vitro
vivo
trial
vitro
trial
carri
vari
cell
line
half
maxim
inhibitori
concentr
half
maxim
effect
concentr
test
drug
extract
unavail
report
half
maxim
inhibitori
concentr
valu
world
health
organ
categor
priorit
total
studi
includ
experi
three
trial
carri
monkey
rhesu
macaqu
whilst
remain
studi
carri
small
anim
model
mice
hamster
guinea
pig
summar
main
characterist
clinic
studi
select
tabl
ii
includ
case
case
nonrandom
cohort
convalesc
blood
product
includ
treatment
regimen
total
final
end
point
extract
mortal
rate
adequ
document
end
point
share
studi
total
select
studi
anim
clinic
assess
risk
bia
within
studi
supplementari
file
anim
studi
found
high
risk
bia
except
studi
unclear
risk
bia
high
risk
bia
anim
studi
mainli
due
select
bia
perform
bia
detect
bia
anim
studi
fail
mitig
select
bia
test
anim
select
without
proper
random
process
thu
sampl
obtain
repres
popul
intend
analyz
anim
studi
also
fail
mitig
perform
bia
detect
bia
blind
investig
clinic
studi
singl
case
report
case
seri
studi
nonrandom
cohort
studi
studi
case
studi
judg
poor
report
qualiti
judg
fair
report
qualiti
last
good
report
qualiti
nonrandom
cohort
found
low
risk
bia
due
signific
variat
select
studi
type
design
particip
report
outcom
measur
chose
carri
narr
synthesi
result
rather
metaanalysi
base
elig
criteria
select
total
potenti
therapeut
agent
treatment
evd
analysi
summar
data
extract
potenti
drug
tabl
iii
chloroquin
readili
avail
welltoler
antimalari
agent
long
histori
use
treatment
prophylaxi
malaria
also
well
document
antivir
effect
variou
stage
viral
life
cycl
includ
well
inhibitori
effect
sever
acut
respiratori
viru
syndrom
addit
studi
show
system
antiinflammatori
effect
chloroquin
downregul
product
proinflammatori
factor
interferon
ifn
tumor
necrosi
potenti
activ
chloroquin
ebola
viru
may
achiev
inhibit
viru
entri
host
cell
believ
take
place
inhibit
variou
factor
vesicl
sort
endosomemembran
fusion
well
increas
endosom
chloroquin
shown
success
inhibit
ebola
viru
vitro
differ
studi
variou
cell
anim
studi
hand
reveal
mix
result
madrid
et
carri
anim
trial
mice
surviv
ebola
infect
treat
chloroquin
twice
daili
mgkg
ip
anoth
studi
intraperiton
treatment
chloroquin
dose
show
signific
protect
high
toxic
mous
hamster
madrid
et
abl
reproduc
posit
result
upon
repeat
test
chloroquin
ebolainfect
mice
ident
condit
mgkg
ip
twice
daili
chloroquin
administ
oral
mgkg
daili
show
increas
search
yield
clinic
trial
chloroquin
mix
result
provid
anim
studi
may
explain
rang
dose
test
higher
dose
may
necessari
produc
consist
posit
result
may
lead
poor
outcom
due
increas
drug
relat
toxic
furthermor
chloroquin
may
effect
given
prophylact
due
activ
earli
stage
viral
cycl
henc
addit
anim
studi
dose
find
recommend
clinic
trial
amodiaquin
antimalari
agent
structur
relat
chloroquin
wide
use
africa
vitro
amodiaquin
shown
inhibit
ebola
viru
well
marburg
viru
potent
chloroquin
demonstr
lower
valu
howev
anim
studi
yield
search
mice
treat
mgkg
ip
amodiaquin
twice
daili
day
show
surviv
retrospect
observ
studi
patient
evd
switch
antimalari
contain
lumefantrin
amodiaquin
associ
signific
decreas
case
fatal
rate
san
evd
treatment
remain
unknown
whether
improv
surviv
rate
due
antivir
activ
amodiaquin
possibl
toxic
lumefantrin
anoth
limit
studi
unmeasur
patient
characterist
ie
confound
variabl
could
influenc
mortal
rate
toremiphen
clomiphen
wellestablish
select
estrogen
reuptak
modul
approv
treatment
breast
cancer
infertil
respect
drug
abl
inhibit
ebola
viru
entri
vitro
like
result
latestag
entri
inhibit
affect
trigger
mous
model
anim
treat
mgkg
ip
clomiphen
surviv
lethal
dose
ebola
viru
toremiphen
treatment
group
mice
treat
drug
mgkg
surviv
two
control
group
show
surviv
anoth
anim
studi
mice
treat
mgkg
ip
clomiphen
twice
daili
show
surviv
benefit
compar
control
addit
anim
trial
differ
dose
essenti
confirm
surviv
benefit
associ
drug
certain
concern
limit
practic
use
toremiphen
clomiphen
evd
therapeut
agent
higher
dose
standard
clinic
rang
may
necessari
achiev
therapeut
effect
evd
would
increas
risk
seriou
side
effect
includ
ocular
advers
effect
clomiphen
seriou
electrolyt
derang
toremiphen
drug
may
therefor
better
suit
candid
combin
treatment
ifn
signal
protein
produc
secret
host
cell
respons
pathogen
tumor
cell
current
approv
treatment
hepat
well
certain
autoimmun
disord
like
multipl
recent
viral
outbreak
ifn
suggest
potenti
treatment
emerg
viral
infect
sever
acut
respiratori
syndrom
antivir
activ
ifn
appear
occur
via
induct
ifnsinduc
transmembran
protein
inhibit
broad
rang
virus
differ
stage
viru
life
cycl
includ
viral
entri
potenti
use
ifn
treatment
evd
assess
sever
studi
sinc
vitro
studi
shown
potent
inhibit
evd
across
multipl
cell
type
anim
studi
shown
protect
mice
challeng
lethal
dose
ebola
two
addit
studi
involv
nonhuman
primat
treat
reveal
increas
surviv
time
chang
despit
potenti
increas
avail
ifn
therapeut
sever
concern
practic
use
evd
outbreak
certain
side
effect
ifn
fever
myalgia
may
difficult
control
evd
treatment
unit
addit
import
rule
comorbid
malaria
interferon
treatment
may
difficult
achiev
may
delay
treatment
transfus
blood
product
establish
treatment
method
varieti
noninfecti
condit
case
infecti
diseas
sever
report
offlabel
use
convalesc
blood
chose
includ
convalesc
blood
product
assess
due
similar
properti
share
repurpos
therapeut
includ
presum
avail
set
evd
epidem
posit
report
toler
absenc
safetyrel
event
nonrandom
nonetheless
import
note
transfusiontransmit
infect
remain
signific
problem
africa
may
difficult
distinguish
transfusionrel
complic
evd
use
whole
blood
form
passiv
immunotherapi
treatment
evd
report
evd
outbreak
democrat
republ
congo
observ
studi
patient
receiv
convalesc
blood
transfus
surviv
contrast
mortal
rate
outbreak
howev
survivor
receiv
convalesc
blood
day
day
onset
symptom
separ
analysi
shown
high
rate
surviv
due
treatment
patient
later
cours
diseas
higher
probabl
recent
west
africa
evd
outbreak
world
health
organ
approv
use
blood
plasma
transfus
convalesc
search
yield
singl
case
report
foreign
patient
contract
evd
stay
western
africa
surviv
follow
transfus
addit
potenti
therapeut
agent
administ
largest
studi
treatment
evd
convalesc
blood
enrol
confirm
evd
patient
san
treatment
unit
guinea
includ
primari
studi
show
signific
improv
surviv
patient
receiv
ml
convalesc
plasma
unknown
level
neutral
antibodi
even
adjust
age
cyclethreshold
valu
recent
publish
studi
sierra
similarli
show
signific
improv
surviv
reveal
signific
drop
viral
load
hour
treatment
convalesc
whole
blood
furthermor
result
recent
anim
studi
mire
et
show
protect
treatment
rhesu
monkey
convalesc
sera
remain
unknown
whether
convalesc
blood
product
known
titer
antiebola
viru
antibodi
altern
administr
regimen
subselect
patient
would
yield
differ
result
amiodaron
wide
avail
commonli
use
multiion
channel
blocker
approv
treatment
atrial
fibril
ventricular
tachycard
arrhythmia
identifi
potent
inhibitor
ebola
viru
variou
endotheli
epitheli
cell
line
concentr
commonli
reach
human
treat
mechan
action
appear
reli
induct
niemannpick
clike
phenotyp
inhibit
late
endosom
filoviru
small
anim
studi
yield
search
treatment
mgkg
amiodaron
ip
twice
daili
significantli
improv
surviv
ebola
viruschalleng
mice
repeat
trial
ident
condit
unabl
reproduc
signific
improv
surviv
furthermor
amiodaron
reportedli
use
sierra
leon
treat
evd
patient
treatment
unit
compassion
basi
potenti
effect
statist
signific
could
therapeut
agent
appear
inhibit
filoviru
entri
similar
fashion
amiodaron
sertralin
bepridil
sertralin
select
serotonin
reuptak
inhibitor
use
treatment
depress
bepridil
calcium
channel
blocker
use
treat
angina
pectori
drug
found
effect
inhibit
ebola
viru
vitro
murin
model
mice
treat
mgkg
sertralin
twice
daili
surviv
compar
mortal
control
group
studi
mice
treat
mgkg
bepridil
favipiravir
rel
new
viral
rna
polymeras
inhibitor
approv
japan
pharmaceut
medic
devic
agenc
treatment
influenza
viru
infect
consid
broadspectrum
antivir
activ
rna
virus
demonstr
activ
hemorrhag
fevercaus
virus
arenavirus
unfold
antivir
activ
favipiravir
initi
convert
activ
metabolit
act
rna
polymeras
inhibitor
mainli
via
direct
competit
gtp
addit
favipiravir
caus
lethal
mutagenesi
incorpor
viral
studi
ebola
viru
involv
favipiravir
shown
promis
outcom
vitro
small
anim
anim
studi
differ
mice
model
treatment
regimen
treatment
favipiravir
associ
surviv
howev
outcom
phase
ii
clinic
trial
nonrandom
cohort
studi
patient
stratifi
base
baselin
cycl
threshold
valu
reflect
viral
load
patient
moder
high
viremia
cycl
threshold
valu
show
tendenc
lower
mortal
rate
compar
histor
record
although
differ
statist
singlecent
retrospect
studi
bai
et
seri
treat
patient
medium
high
viral
load
show
significantli
higher
surviv
rate
compar
control
group
addit
random
multicent
trial
necessari
confirm
efficaci
target
group
elimin
confound
variabl
azithromycin
wellestablish
antibiot
commonli
prescrib
treatment
variou
bacteri
infect
addit
propos
antivir
activ
treatment
upper
respiratori
tract
viral
effect
believ
result
amplif
system
antivir
respons
mediat
ifn
pathway
known
direct
antivir
inhibitori
effect
azithromycin
among
sever
drug
investig
antiebola
viru
activ
vitro
small
anim
shown
potent
vitro
inhibit
ebola
viru
small
anim
studi
gener
mix
result
murin
model
treatment
mgkg
azithromycin
twice
daili
initi
associ
surviv
rate
compar
control
group
p
repeat
test
ident
condit
reproduc
statist
signific
result
addit
differ
treatment
regimen
mgkg
oral
azithromycin
po
daili
associ
surviv
rate
efficaci
screen
use
differ
dose
azithromycin
guinea
pig
similarli
yield
posit
systemat
review
carri
basi
previous
publish
protocol
comprehens
search
select
relev
studi
identifi
potenti
repurpos
drug
evd
howev
limit
either
inher
methodolog
appli
review
studi
includ
still
exist
first
despit
search
strategi
design
highli
sensit
certain
studi
topic
captur
due
press
natur
acut
evd
epidem
result
rapidli
evolv
research
scene
mani
studi
current
second
review
synthes
narr
may
increas
risk
bia
studi
given
weight
compar
effort
avoid
bia
review
includ
systemat
select
articl
extract
data
identif
potenti
drug
author
independ
multireview
extract
previous
shown
decreas
risk
error
compar
singlereview
sever
limit
inher
studi
includ
review
first
clear
major
includ
studi
categor
screen
vitro
anim
studi
result
studi
use
reliabl
predict
posit
respons
review
studi
carri
nonhuman
primat
consid
gold
standard
filoviru
model
resembl
human
clinic
manifest
filovir
remain
anim
studi
carri
use
adapt
small
anim
model
mice
hamster
guinea
pig
natur
suscept
ebola
viru
studi
necessari
use
genet
adapt
viru
undergon
numer
mutat
achiev
virul
lethal
genet
variat
adapt
ebola
viru
togeth
differ
diseas
develop
compar
infect
human
limit
abil
extrapol
result
studi
furthermor
risk
bia
assess
reveal
high
risk
bia
anim
studi
limit
appear
share
concern
amongst
field
drug
review
includ
total
clinic
studi
high
level
intern
valid
high
level
evid
base
oxford
level
studi
case
report
case
seri
low
level
trial
nonrandom
studi
midrang
level
lack
highlevel
evid
may
sever
reason
first
recent
evd
epidem
condit
neglect
major
clinic
research
attempt
carri
second
clinic
research
outbreak
face
mani
ethic
practic
obstacl
influenc
studi
design
number
particip
systemat
review
offer
comprehens
overview
current
state
art
regard
drug
repurpos
evd
address
differ
stage
repurpos
drug
develop
evd
screen
chemic
librari
clinic
trial
author
review
identifi
therapeut
agent
potenti
promis
therapeut
influenc
evd
stage
none
therapeut
agent
recommend
treatment
evd
review
highlight
need
welldesign
wellconduct
preclin
clinic
research
establish
efficaci
drug
propos
indic
may
use
aid
research
identifi
gap
evid
variou
drug
present
author
indic
conflict
interest
regard
content
articl
